Follow
Ibrahim Ince
Ibrahim Ince
Expert Systems Pharmacology and Medicine
Verified email at unity-mail.de - Homepage
Title
Cited by
Cited by
Year
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations
I Ince, CAJ Knibbe, M Danhof, SN de Wildt
Clinical pharmacokinetics 52, 333-345, 2013
1012013
Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic …
A Dallmann, I Ince, M Meyer, S Willmann, T Eissing, G Hempel
Clinical pharmacokinetics 56, 1303-1330, 2017
1002017
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK–PD modeling
I Ince, SN de Wildt, D Tibboel, M Danhof, CAJ Knibbe
Drug discovery today 14 (5-6), 316-320, 2009
772009
Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women
A Dallmann, I Ince, J Solodenko, M Meyer, S Willmann, T Eissing, ...
Clinical pharmacokinetics 56, 1525-1541, 2017
762017
A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways
A Dallmann, I Ince, K Coboeken, T Eissing, G Hempel
Clinical pharmacokinetics 57, 749-768, 2018
742018
Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years
I Ince, SN De Wildt, MYM Peeters, DJ Murry, D Tibboel, M Danhof, ...
Therapeutic drug monitoring 34 (4), 381-389, 2012
552012
A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults
I Ince, SN de Wildt, C Wang, MYM Peeters, J Burggraaf, E Jacqz-Aigrain, ...
Clinical pharmacokinetics 52, 555-565, 2013
542013
Applied concepts in PBPK modeling: how to extend an open systems pharmacology model to the special population of pregnant women
A Dallmann, J Solodenko, I Ince, T Eissing
CPT: pharmacometrics & systems pharmacology 7 (7), 419-431, 2018
452018
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds
AA Somani, K Thelen, S Zheng, MN Trame, K Coboeken, M Meyer, ...
British Journal of Clinical Pharmacology 81 (1), 137-147, 2016
392016
Predictive pediatric modeling and simulation using ontogeny information
I Ince, J Solodenko, S Frechen, A Dallmann, C Niederalt, J Schlender, ...
The Journal of Clinical Pharmacology 59, S95-S103, 2019
302019
A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug …
S Frechen, J Solodenko, T Wendl, A Dallmann, I Ince, T Lehr, J Lippert, ...
CPT: pharmacometrics & systems pharmacology 10 (6), 633-644, 2021
172021
Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery
A Dallmann, A Himstedt, J Solodenko, I Ince, G Hempel, T Eissing
Journal of pharmacokinetics and pharmacodynamics 47 (4), 341-359, 2020
162020
Predictive performance of physiology‐based pharmacokinetic dose estimates for pediatric trials: evaluation with 10 Bayer small‐molecule compounds in children
I Ince, A Dallmann, S Frechen, K Coboeken, C Niederalt, T Wendl, ...
The Journal of Clinical Pharmacology 61, S70-S82, 2021
152021
Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets–Implications for quality control and application
H Stass, S Just, B Weimann, I Ince, S Willmann, E Feleder, C Freitas, ...
European Journal of Pharmaceutical Sciences 166, 105940, 2021
82021
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
S Willmann, K Coboeken, Y Zhang, H Mayer, I Ince, E Mesic, K Thelen, ...
CPT: Pharmacometrics & Systems Pharmacology 10 (10), 1195-1207, 2021
62021
Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
S Frechen, I Ince, A Dallmann, M Gerisch, N Jungmann, C Becker, ...
European Heart Journal 41 (Supplement_2), ehaa946. 3329, 2020
42020
Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults–an AGePOP review
C Demeester, D Robins, AE Edwina, J Tournoy, P Augustijns, I Ince, ...
European Journal of Pharmaceutical Sciences, 106496, 2023
32023
Population pharmacokinetics of nifurtimox in adult and pediatric patients with Chagas disease
I Ince, K Prins, S Willmann, G Sutter, E Hanze, F Sadre‐Marandi, H Stass, ...
The Journal of Clinical Pharmacology 62 (10), 1273-1284, 2022
32022
Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
S Willmann, I Ince, M Ahsman, K Coboeken, Y Zhang, K Thelen, ...
CPT: Pharmacometrics & Systems Pharmacology 11 (8), 1111-1121, 2022
32022
Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding
H Stass, I Ince, U Grossmann, B Weimann, S Willmann
The AAPS Journal 24 (5), 92, 2022
22022
The system can't perform the operation now. Try again later.
Articles 1–20